Cardioprotective mechanisms of novel noncoding RNA in myocardial infarction
新型非编码RNA对心肌梗死的心脏保护机制
基本信息
- 批准号:10660164
- 负责人:
- 金额:$ 64.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:Acute myocardial infarctionAdoptive TransferAntisense OligonucleotidesAttentionBindingBiodistributionBiologicalBiological AvailabilityCardiotonic AgentsCaseinsCell NucleusCell SurvivalCell TherapyCellsChemicalsChronicDataDevelopmentDichloromethylene DiphosphonateDiseaseDuchenne muscular dystrophyEFRACFDA approvedGatekeepingGene ExpressionGenesHeartHeart DiseasesHeart failureHuman MilkIn VitroInfarctionInflammatoryInjuryInterleukin-10IntravenousIschemiaLeftLinkMacrophageMeasuresMediatingMediatorMessenger RNAMilk ProteinsModelingMusMyocardial InfarctionNecrosisNuclear Pore Complex ProteinsNucleotidesOralOral AdministrationOutcomePathway interactionsPeptidesPharmaceutical PreparationsPropertyRNARationalizationReperfusion TherapyRoleSmall Interfering RNATestingThinkingTissuesTransplantationUntranslated RNAWorkagedaptamercardioprotectioncytokinedosageexosomeextracellular vesiclesin vivoinsightmouse modelmutantnew chemical entitynovelparacrinepreservationprototyperegenerative cellregenerative therapytranscriptomicstranslational potential
项目摘要
PROJECT SUMMARY/ABSTRACT
This proposal seeks to understand the cardioprotective effects of a new noncoding RNA (ncRNA) entity, TY4,
that is bioinspired by the contents of exosomes. Our focus is on one class of small ncRNA, not previously
recognized as particularly relevant to cardiac disease. Y RNAs captured our attention because molecules
encoded by the YRNA4 gene are exceptionally plentiful in exosomes secreted by cardiosphere-derived cells.
The predominant such ncRNA, EV-YF1, has salutary properties when delivered on its own: EV-YF1 increases
IL-10 secretion, is cardioprotective and anti-hypertrophic. Here we present preliminary data on TY4, a new
chemical entity (NCE) bioinspired by EV-YF1. TY4 exerts global transcriptomic changes involving inflammatory
and fibrotic pathways, and exerts disease-modifying bioactivity in murine models of heart failure with preserved
ejection fraction, Duchenne muscular dystrophy, and MI. Remarkably, TY4, when formulated with the breast milk
protein casein, works orally in all three models. In terms of mechanism, preliminary data show that TY4 binds to
TPR, a nuclear pore complex protein that acts as a gatekeeper for messenger RNA export from the nucleus. We
have also found that macrophage depletion abrogates TY4-mediated cardioprotection. As a small chemically-
modified mutant NCE, TY4 has key features desirable in a synthetic RNA drug. But other RNA drugs, whether
FDA-approved or in development, all have known mechanisms of action: they are antisense oligos, small
interfering RNAs, aptamers, or miR-modifiers. TY4 fits into none of those classes and thus is the prototype for a
new class of RNA drugs. The focus here is on understanding the mechanism whereby TY4 limits infarct size.
We will test the following mechanistic hypothesis: TY4 is cardioprotective against MI by binding to TPR and
altering gene expression in target cells (and specifically, in macrophages). We will pursue the following Aims: 1:
Investigate the mechanism(s) whereby TY4 alters gene expression in macrophages. Sub-aims seek to
identify TY4 binding partners, characterize the transcriptomic changes induced by TY4, and prioritize biological
targets for further interrogation. 2: Optimize in vivo efficacy of oral TY4 in murine MI. Sub-aims seek to
optimize the dosage paradigm for oral TY4 in acute MI, measure biodistribution of TY4 after oral delivery in mice
pre- and post- acute MI, determine the window of opportunity for TY4 efficacy post-MI in acute MI, test TY4
cardioprotective efficacy in aged mice, and characterize the effects of optimized oral TY4 delivery in a chronic
MI model. 3: Test whether macrophages are necessary and sufficient to explain TY4 efficacy in acute MI.
Sub-aims seek to compare MI outcomes +/- TY4 with and without prior macrophage depletion, probe the relative
roles of tissue-resident versus circulating macrophages, and determine whether post-MI adoptive transfer of ex
vivo TY4-conditioned macrophages reduces infarct size in macrophage-depleted mice. While highly mechanistic,
our proposal, focusing on a synthetic ncRNA NCE bioinspired by exosomal cargo, also offers translational value
in its development of a novel cardioprotective agent that is effective even when given after reperfusion.
项目摘要/摘要
这项提议试图了解一种新的非编码RNA(NcRNA)实体TY4的心脏保护作用。
这是受到外体内容的生物启发。我们的重点是一类小的ncRNA,而不是以前的
被公认为与心脏病特别相关的。Y RNA吸引了我们的注意力,因为分子
由YRNA4基因编码的蛋白在心球来源的细胞分泌的外切体中异常丰富。
这种主要的ncRNA,EV-YF1,当它自己递送时具有有益的特性:EV-YF1增加
分泌IL-10,具有心脏保护和抗肥大作用。在这里,我们提供了TY4的初步数据,这是一种新的
EV-YF1生物启发的化学实体(NCE)。TY4在全球转录水平上发生变化,涉及炎症
和纤维化途径,并在保存的心力衰竭小鼠模型中发挥疾病修改生物活性
射血分数、杜氏肌营养不良和心肌梗死。值得注意的是,当TY4与母乳一起配方时
蛋白质酪蛋白在所有三种模型中都有口服作用。在机制方面,初步数据显示,TY4结合到
TPR是一种核孔复合体蛋白,它充当信使RNA从细胞核输出的守门人。我们
他们还发现,巨噬细胞的耗尽破坏了TY4介导的心脏保护。作为一种小的化学物质-
修饰突变体NCE,TY4具有合成RNA药物所需的关键特征。但其他RNA药物,无论是
FDA批准的或正在开发中的所有药物都有已知的作用机制:它们是反义寡核苷酸,小
干扰RNA、适配子或miR修饰物。TY4不属于这些类,因此是
新型核糖核酸类药物。这里的重点是了解TY4限制梗塞范围的机制。
我们将检验以下机制假设:TY4通过与TPR和TPR结合而对心肌梗死具有心脏保护作用
改变靶细胞(特别是巨噬细胞)的基因表达。我们将追求以下目标:1.
探讨TY4改变巨噬细胞基因表达的机制(S)。子目标寻求
确定TY4结合伙伴,表征TY4诱导的转录变化,并优先考虑生物
进一步审讯的目标。2.优化TY4口服液对小鼠心肌梗死的体内疗效。子目标寻求
优化急性心肌梗死口服TY4给药方案,测定口服TY4在小鼠体内的生物分布
急性心肌梗死前后,确定急性心肌梗死后TY4疗效的机会窗,测试TY4
老年小鼠的心脏保护作用,以及优化口服TY4对慢性心肌梗死的影响
MI模型。3:测试巨噬细胞是否是解释急性心肌梗死TY4疗效的必要条件和充分条件。
子目标寻求比较+/-TY4在有和没有先前巨噬细胞耗竭的情况下的心肌梗死结果,探索相对的
组织驻留巨噬细胞与循环巨噬细胞的作用,并确定心肌梗死后是否过继转移EX
体内TY4条件下的巨噬细胞减少了巨噬细胞耗竭小鼠的梗塞面积。虽然高度机械化,
我们的建议,专注于合成ncRNA nce生物灵感来自外体货物,也提供了翻译价值
正在开发一种新的心脏保护剂,即使在再灌流后也是有效的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDUARDO MARBAN其他文献
EDUARDO MARBAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDUARDO MARBAN', 18)}}的其他基金
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10296255 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10657415 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Exosome Therapeutics to Dissect HFpEF Mechanisms
外泌体疗法剖析 HFpEF 机制
- 批准号:
10427452 - 财政年份:2021
- 资助金额:
$ 64.13万 - 项目类别:
Cardioprotective mechanisms of cell therapy for myocardial infarction
细胞治疗心肌梗死的心脏保护机制
- 批准号:
9906252 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
8759304 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
8890879 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Exosome-mediated cardioprotection and regeneration
外泌体介导的心脏保护和再生
- 批准号:
9047307 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别:
Electrophysiology and Cell Biology of Cardiac Stem Cells
心脏干细胞的电生理学和细胞生物学
- 批准号:
7391523 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
Dedifferentiation of cardiomyocytes into cardiac progenitor cells
心肌细胞去分化为心脏祖细胞
- 批准号:
8436173 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
Dedifferentiation of cardiomyocytes into cardiac progenitor cells
心肌细胞去分化为心脏祖细胞
- 批准号:
8039709 - 财政年份:2006
- 资助金额:
$ 64.13万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 64.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 64.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 64.13万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 64.13万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 64.13万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 64.13万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 64.13万 - 项目类别: